Growing up next to a women and children’s hospital where her mother practiced, Xiaolin always wanted to be part of the healthcare industry. Leading a clinical development organization working on novel therapeutics is a perfect fit for her aspiration to help patients. With over 20 years of experience in all phases of clinical development across a wide range of therapeutic areas, including solid tumors, lymphoid and myeloid malignancies and others, she will be responsible for clinical science, clinical operations, biometrics, and pharmacovigilance.
Previously, Xiaolin was VP of Biometrics at Acerta Pharma, where she managed biostatistics, statistical programming, and data management, and was a member of the Senior Management Committee. She was a key contributor to the overall development strategy and approval of Calquence® (BTKi) for relapsed/refractory mantel cell lymphoma. Prior to Acerta, she was VP of Biometrics and Development Operations at Geron, where she managed biometrics, clinical operations, medical writing, and DMPK. Before Geron, she spent 11 years at Genentech, where she made significant contributions to Avastin®, Tarceva®, Herceptin®, and Xolair®. At Genentech, she held a number of leadership positions, including development team lead for Xolair and filing team lead for multiple BLA/sBLA’s.
Xiaolin started her industry career at Millennium Pharmaceuticals after receiving her Doctor of Science degree in Biostatistics from Harvard University. She also holds a Bachelor of Science degree in Probability and Statistics from Peking University in China and a Master of Science degree in Statistics from University of Washington, Seattle.
What is Xiaolin Wang's net worth?
The estimated net worth of Xiaolin Wang is at least $1.35 million as of December 19th, 2022. Ms. Wang owns 30,527 shares of Revolution Medicines stock worth more than $1,345,020 as of December 21st. This net worth estimate does not reflect any other investments that Ms. Wang may own. Additionally, Ms. Wang receives an annual salary of $633,740.00 as Insider at Revolution Medicines. Learn More about Xiaolin Wang's net worth.
How old is Xiaolin Wang?
Ms. Wang is currently 53 years old. There are 5 older executives and no younger executives at Revolution Medicines. The oldest executive at Revolution Medicines is Dr. Stephen M. Kelsey FRC Path., FRCP, M.D., President of Research & Development, who is 63 years old. Learn More on Xiaolin Wang's age.
What is Xiaolin Wang's salary?
As the Insider of Revolution Medicines, Inc., Ms. Wang earns $633,740.00 per year. There are 4 executives that earn more than Ms. Wang. The highest earning executive at Revolution Medicines is Dr. Mark A. Goldsmith Ph.D., CEO, President & Chairman, who commands a salary of $1,120,000.00 per year. Learn More on Xiaolin Wang's salary.
How do I contact Xiaolin Wang?
Has Xiaolin Wang been buying or selling shares of Revolution Medicines?
Xiaolin Wang has not been actively trading shares of Revolution Medicines over the course of the past ninety days. Most recently, Xiaolin Wang sold 708 shares of the business's stock in a transaction on Monday, December 19th. The shares were sold at an average price of $22.94, for a transaction totalling $16,241.52. Following the completion of the sale, the insider now directly owns 30,527 shares of the company's stock, valued at $700,289.38. Learn More on Xiaolin Wang's trading history.
Who are Revolution Medicines' active insiders?
Revolution Medicines' insider roster includes Jack Anders (Insider), Jeff Cislini (General Counsel), Mark Goldsmith (Insider), Margaret Horn (COO), Stephen Kelsey (President, Research & Development), Lorence Kim (Director), Vincent Miller (Director), Sushil Patel (Director), Thilo Schroeder (Director), Peter Svennilson (Director), Xiaolin Wang (Insider), and Barbara Weber (Director). Learn More on Revolution Medicines' active insiders.
Are insiders buying or selling shares of Revolution Medicines?
In the last twelve months, Revolution Medicines insiders bought shares 1 times. They purchased a total of 1,304,347 shares worth more than $59,999,962.00. In the last twelve months, insiders at the sold shares 28 times. They sold a total of 271,841 shares worth more than $11,976,056.91. The most recent insider tranaction occured on December, 16th when COO Margaret A Horn sold 4,329 shares worth more than $196,536.60. Insiders at Revolution Medicines own 8.0% of the company.
Learn More about insider trades at Revolution Medicines. Information on this page was last updated on 12/16/2024.
